chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Itch on her back; Rash on her back; A spontaneous report was received from a consumer concerning a 78-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced pruritus (itch on her back) and rash (rash on her back).  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 26 Feb 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 025A21A) intramuscularly for prophylaxis of COVID-19 infection.  On an unknown date, the patient experienced Itch and Rash on her back.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events was unknown.
2 1/4" x 1 3/4" raised red lesion (wheal+flare) at injection site of MMR and DTaP.
Red blotchy, hot, swollen, sore & tender to the touch Tylenol for TX
Herpes on lip, all joints aching, temperature, hot and cold shivering, headache, moaning in pain. Took Excedrin. 24 hours
didn't receive full dose; it leaked through the arm; it leaked through the arm; This case was reported by a nurse via call center representative and described the occurrence of incomplete dose administered in a 13-year-old female patient who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2021-2022 season) (batch number 93Z32, expiry date 30th June 2022) for prophylaxis.   Co-suspect products included flu seasonal qiv dresden pre-filled syringe device (Fluarix Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 9th December 2021, the patient received Fluarix Quadrivalent 2021-2022 season and Fluarix Tetra Pre-Filled Syringe Device. On 9th December 2021, unknown after receiving Fluarix Quadrivalent 2021-2022 season and Fluarix Tetra Pre-Filled Syringe Device, the patient experienced incomplete dose administered, inadvertent exposure to vaccine and exposure via skin contact. On an unknown date, the outcome of the incomplete dose administered, inadvertent exposure to vaccine and exposure via skin contact were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient did not receive full dose of Fluarix since it leaked through the arm while another nurse was administering it, which led to incomplete dose administered, inadvertent exposure to vaccine and exposure via skin contact. The reporter confirmed that, this was maladministration by the other nurse since she was new at given injections. The syringe was intact. The reporter consented to follow up.
Received PNEUMOVAX and FLUZONE-HD on 10/1/12. That evening she developed fever and malaise which lasted several days. The injection site became red, inflamed and swollen and spread down arm.
pt recvd vax;awoke from nap experiencing  screaming;saw PMD; screaming subsided later;
Breathing changed, chest seemed heavy and mind seemed cloudy. Slept most of the night. Woke up with a migraine. Approx 1 week later the injection site had approx 1 inch red area at injection site as well as itching and raised bumps. Symptoms lasted approx 7 days.
Patient tested positive for COVID six days after receiving her first COVID-19 vaccination. Her symptoms began one day earlier on 1/20/21. She went to the hospital on 1/23/21 but was sent home. She was later taken back to the hospital and admitted to ICU on 1/25/21.
Rash on face  - a dark red welt in a straight line about 2 inches long on my face with red spots in - resembled shingles strongly. Did not hurt or itch. Lasted about 4 days.
Patient had COVID vaccine.  Exited vac room & sat in waiting chair by her mother.  A few minutes later came out of the vaccine room to let mother know it was her turn for vaccine.  Mother said patient was going to pass out.   the mother supported the patient as she passed out & they slid down to the floor.  yelled for the pharmacist & called 911. Got her feet up, cold packs to cool & water.  EMTs came, bp ok, sugars ok. Denied ambulance. Rested then left with mother.
Headache and light headedness Weakness Skin sensitivity Took 800mg Ibuprofen, went to bed, and in one hour felt fine.
This spontaneous report was received from a physician assistant referring to a patient of unknown age and gender. No pertinent medical history and cocurrent condition reported. On 08-JUL-2014 the patient received an expired dose of PNEUMOVAX 23 (lot # H015749), intramuscular (dose not reported). No other concomitant therapies reported. No known adverse effects reported. The outcome of the events was unknown. No PQC reported. Additional information has been requested.
I got Longhaul COVID symptoms after the vaccine. Prior to the vaccine, I did NOT have these symptoms. My initial infection was in October of 2020. This was almost a year later. I currently have left sided chest pressure daily, PEM, chronic fatigue, insomnia, brain fog, neuralgia, frequent palpitations, flat ribbon stools, and dark, foamy urine.
PT ACCIDENTALLY GOT SECOND FLU SHOT, MISCOMMUICATION , ALSO GOT COVID BOOSTER
Noon shot; went back to work. Arm was sore and I was tired. Went home and went to bed. Had fever and shakes the next morning at 09:00. Went to doctor's office and fever was 104F but shakes had stopped. Benadryl, Celebrex and Bextra given by doctor. Pt improved. DX: Anaphylactic/allergy to either Pneumonia or Infanrix.
Case number PHEH2014US025037, is an initial spontaneous report from a nurse received on 09 Dec 2014. This report refers to a 72-year-old female patient. Historical conditions were not reported. No concomitant medication was reported. The patient was vaccinated with FLUVIRIN (batch number: 145701) intramuscularly at a dose of 0.5 ml on 28 Oct 2014. The nurse reported that FLUVIRIN administered had 12 separate temperature excursions lasting for 30 minutes over a period of 34 days. The temperature excursion began on 16 Oct 2014 and the temperature was between 46 to 49 degree F during the excursion. No adverse event reported following this medication error.
The patient developed severe arthralgias of multiple joints including bilateral knees, wrists, shoulders 2 days after the second dose of Covid 19 vaccine.  The patient has had progressive pain of multiple joints, and migratory arthralgias for 2 weeks.  He was evaluated 5/25/2021 initially and no source for his symptoms was found.  Throughout the 2 weeks he has had no headaches, dizzyness, lateralizing neurological symptoms, but he did have profuse diaphoresis and mild myalgias.  3 weeks after the onset of symptoms patient has been diagnosed with Parvovirus infection reactivation due to the vaccine.  He is responding to Prednisone 60 mg x 2 days, 40 mg x 3 days, 20 mg daily for 5 days and taper as tolerated.  Patient also received Doxycycline for tick borne illness treatment until labs were negative.  He received Percocet for pain management and Tramadol.
Inconsolable for multiple hours, fever 101 for more than 48 hours.  Treatment was to continue with Motrin.
pfizer covid vaccine was given about 4:30pm and patient was instructed to stay in store for 15 minutes.  she and her party left the vaccination room and headed down the aisle to get a drink from the refrigerated section.  her mother said she became weak and nearly passed out.  mother saw me and asked me for help.  she carried her back to the waiting area and sat her on a chair.    she was awake but looked pale and seemed somewhat incoherent.  she was clammy.  she said she was breathing fine and appeared to be breathing fine, and there was no sign of swelling.   she was given some water.  i called the paramedics and  described what happened.  the paramedics arrived within approximately 10 minutes of the start of the incident.  she never passed out while i was watching her but mom said she felt she had passed out at the start of the incident.  the paramedics spent about 10 minutes with her at which time i returned to my duties in the pharmacy.   when they were done i went back to find out what they had determined.  the patient and her mother did not opt for transportation to the hospital and they said she was better now.  she was visibly better.  paramedics advised them what to do if her condition began to worsen.  they went home at that time.  i called later in the evening, about 9 pm to check on her condition.  mam said she was doing better.
This spontaneous report was received from a medical assistant and refers to an unspecified number of patients of unknown age and gender. The patients' concurrent conditions, pertinent medical history and concomitant medications were not reported. On unspecified dates, unspecified patients were administered with an improperly stored ROTATEQ (orally; dose was not provided; lot # reported as L008054 and expiration date on 30-NOV-2016). No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Patient was given vaccines. Left leg was red around the site of varicella vaccine down to the path of the other vaccines.
Event occurred after 2nd dose. Patient was diagnosed of COVID 19 Ascorbic acid, Tylenol In-patient
Arm sore.; Headache for 3 days; Two week mark start the period on birth control.; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 29Jul2021 at 12:00 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. The patient's medical history were reported as no. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications are not reported. On 02Aug2021 at 00:00,  the patient experienced arm sore, headache for 3 days and two week mark start the patient's period on birth control. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events arm sore, headache and two week mark start the period on birth control was recovering at the time of this report.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Swollen left arm and hand; awakened early the next morning  (Sat 2/13/21) by violent shaking, severe chills, severe pain on left side of body from head to tow; terrible headache and pain in my eyes; upset stomach (nausea, etc.) all of this was followed by extreme exhaustion.  It took until late Saturday evening (2/13/21) for the symptoms to begin to subside and I really didn't feel better until the next day (Sun 2/14/21).
Information has been received from a nurse concerning an 11 year old female with no pertinent medical history who on 16-JUL-2008 was vaccinated with the first dose of GARDASIL. On 16-JUL-2008 the patient experienced dizzy, sweaty and her vision darkened right after injection. The patient sat down for a few minutes and the symptoms went away. The patient recovered from dizzy, sweaty and vision darkened. The patient sought medical attention. Additional information has been requested.
3 months since first dose/received my first vaccine May 17th and missed my second vaccine in June; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (3 months since first dose/received my first vaccine May 17th and missed my second vaccine in June) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In June 2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (3 months since first dose/received my first vaccine May 17th and missed my second vaccine in June). In June 2021, PRODUCT DOSE OMISSION ISSUE (3 months since first dose/received my first vaccine May 17th and missed my second vaccine in June) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment information was provided.
RESULTANT  BODY ACHES; CHILLS; SLIGHT NAUSEA; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: UNKNOWN) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the subject experienced resultant body aches, chills, and slight nausea. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the chills, resultant body aches and slight nausea was not reported. This report was non-serious.
Redness and itching at injection site, about 2"x4" in size, talked to nurse told to use Cortisone Cream 3x day, I used Triamcinilon,  on 9/19 and 9/20 I switched to Polysporin because it wasn't itching by was very red, blotchy and maybe a little warm - may have had a blister.  9/22 area started fading, switched back to triamcinilon, stopped cream on 9/27/2011 mostly faded on 9/29/2011
This case was reported by a nurse and described the occurrence of inappropriate age at vaccine administration in a infant male patient who received FLULAVAL (batch number 5ZP94, expiry date June 2015). On an unknown date, the patient received FLULAVAL .25 ml. On an unknown date, an unknown time after receiving FLULAVAL, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown. Additional information received: Nurse reports that she administered a FLULAVAL vaccine to a patient who is under the recommended age for FLULAVAL, no other AEs were reported.
First Dose Given on 3/14/2022 Second Dose Given on 12/05/2022; Patient Had Full Series of Heplisav-B and Did Not Respond; Initial Report Received on 13-Feb-2023  A registered nurse reported that a 63-year-old male patient (race and ethnicity unknown) received a full series of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and did not respond.  Medical history and concomitant medications at the time of vaccination were not reported. The patient has allergies to penicillin.  On 14-Mar-2022, the patient received the first dose of HEPLISAV-B vaccine (Lot # 935849, expiration date 13-Jan-2023; NDC # and route not reported) in the right deltoid.  On 05-Dec-2022, 267 days after having been vaccinated with the first dose of HEPLISAV-B, the patient received the second dose of HEPLISAV-B (Lot # 940487, expiration date 14-Nov-2024; NDC # and route not reported) in the right deltoid. The patient had the full series of HEPLISAV-B and did not respond. The time to titer and the titer result was not specified.  No further information was provided.   Company Comment: The company assessed the events as non-serious. The event was considered non-immunologically confirmed due to dosing schedule and date and results of titer not specified.; Sender's Comments: The company assessed the events as non-serious. The event was considered non-immunologically confirmed due to dosing schedule and date and results of titer not specified.
Exteme itching, redness and swelling. Pt also had fever, chills and aches.
Approximately 15-30 minutes after injection patient reported tingling in his left hand, a strange sensation down his entire left arm, tingling down the left side of his back.  Later on at night he developed a fever of 102 degrees along with profuse sweating.  The fever broke about 4:00 am. Today (7/1) he reports the tingling and strange sensations are gone, his arm is sore near the injection site with a slight lump.
After the first dose, I experienced body aches and fatigue the next day, which stopped after 24 hours. However, I continued (and still have today) to experience aches in my legs and knees. If I sit too long, cross my ankles, cross my legs, kneel down, or try to stand from any prone position, I experience pain and stiffness in both legs, which takes several minutes to subside. I would say the worst is in my knees, though I tend to feel it all throughout my legs.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. No concurrent condition, medical history or allergy/drug reactions were reported. On 23-DEC-2015 at 23:14, the patient was vaccinated with improperly stored RECOMBIVAX HB with lot number: L025738, expiry date: unspecified (dose and strength unspecified). No concomitant medications were reported. No adverse effects were reported. The high and low temperatures were 6.4 and 5.0 (units unspecified) respectively. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of the several reports from the same reporter. Additional information has been requested.
After receiving vaccine patient complaints of feeling unwell, diaphoretic, nausea, increased heart rate. BP elevated at 226/107 HR 140. Patient assisted to stretcher given oral fluids and reassessed. patient states he does have a history of SVT, which he takes diltazem and lisinopril for.
Tiredness; aches and pains and tired; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (aches and pains and tired) and FATIGUE (Tiredness) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-May-2021, the patient experienced MYALGIA (aches and pains and tired). On an unknown date, the patient experienced FATIGUE (Tiredness). On 30-May-2021, MYALGIA (aches and pains and tired) outcome was unknown. At the time of the report, FATIGUE (Tiredness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Anaphylaxis reaction manifesting as hives; most pronounced on both hands and both elbows. I have taken 50 mg of OTC diphenhydramine HCI, and 180 mg of fexofenadine hydrochloride which has lessened the severe itching
diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced DIARRHOEA (diarrhea). The patient was treated with LOPERAMIDE HYDROCHLORIDE (IMODIUM) for Diarrhea, at an unspecified dose and frequency. On 28-Jan-2021, DIARRHOEA (diarrhea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were provided.  It was reported that the patient had the second dose without any issues.  Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Follow-up received updated event stop date and suspect dosage details.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
pain in the injected arm that radiated all the way down to the fingers; Numbness/that radiated all the way down to the fingers/and got progressively worse with numbness; tingling/and got progressively worse with numbness and tingling.; This case was reported by a nurse via sales rep and described the occurrence of pain in arm in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   In May 2020, the patient received the 1st dose of Shingrix. In May 2020, 3 days after receiving Shingrix, the patient experienced pain in arm, numbness and tingling. On an unknown date, the outcome of the pain in arm was recovering/resolving and the outcome of the numbness and tingling were unknown.   It was unknown if the reporter considered the pain in arm, numbness and tingling to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix and on approximately day 3 after Vaccine was given the patient called and reported pain in the injected arm that radiated all the way down to the fingers and got progressively worse with numbness and tingling.  The pain in arm was so bad he made an emergency room visit.  The reporter spoke with patient at the time of reporting and arm was much better.
site of injection has red mark; Site of injection has itchiness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Site of injection has itchiness) and VACCINATION SITE ERYTHEMA (site of injection has red mark) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced VACCINATION SITE PRURITUS (Site of injection has itchiness). On 02-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (site of injection has red mark). At the time of the report, VACCINATION SITE PRURITUS (Site of injection has itchiness) and VACCINATION SITE ERYTHEMA (site of injection has red mark) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. Treatment medication include cortisone cream   Most recent FOLLOW-UP information incorporated above includes: On 03-Jun-2021: Follow up received on 03-JUN-2021 contains no new information.